Published in Tumour Biol on December 08, 2005
Liquid-based cytology aids in primary fallopian tube cancer diagnosis. J Zhejiang Univ Sci B (2009) 0.75
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer (2009) 2.48
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst (2000) 2.34
Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. J Thromb Haemost (2012) 2.17
Antibiotic prophylaxis for hysterectomy, a prospective cohort study: cefuroxime, metronidazole, or both? BJOG (2013) 2.00
Risk of minor and major fetal malformations in diabetics with high haemoglobin A1c values in early pregnancy. Br Med J (Clin Res Ed) (1984) 1.77
Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe. Kidney Int (2006) 1.74
Diagnosis of ectopic pregnancy by vaginal ultrasonography in combination with a discriminatory serum hCG level of 1000 IU/l (IRP) Br J Obstet Gynaecol (1990) 1.65
Factors associated with progression of IgA nephropathy are related to renal function--a model for estimating risk of progression in mild disease. Clin Nephrol (2002) 1.64
Radioimmunoassay of plasma renin activity. Clin Chem (1976) 1.62
Rapid measurement of urinary trypsinogen-2 as a screening test for acute pancreatitis. N Engl J Med (1997) 1.61
Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer (1986) 1.55
Normal early pregnancy: serum hCG levels and vaginal ultrasonography findings. Br J Obstet Gynaecol (1990) 1.53
Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem (1999) 1.52
Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women. Br J Obstet Gynaecol (1993) 1.51
Quantification of prostate specific antigen mRNA levels in circulation after prostatic surgery and endocrine treatment by quantitative reverse transcription-polymerase chain reaction. Scand J Clin Lab Invest (2004) 1.47
Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest (2001) 1.47
Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen. Clin Chem (1995) 1.46
Three assays for glycohemoglobin compared. Clin Chem (1995) 1.45
Correlation of HbA1C, glycated serum proteins and albumin, and fructosamine with the 24-h glucose profile of insulin-dependent pregnant diabetics. Clin Chem (1989) 1.45
Effect of an in vitro fertilization program on serum CA 125, tumor-associated trypsin inhibitor, free beta-subunit of human chorionic gonadotropin, and common alpha-subunit of glycoprotein hormones. Fertil Steril (2000) 1.40
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res (2002) 1.36
In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology (1996) 1.27
Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab (1996) 1.27
Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer (1983) 1.27
Uptake of environmental antigens by the bursa of Fabricius. Nature (1975) 1.23
Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem (1995) 1.21
Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab (2001) 1.20
Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem (1982) 1.20
Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem (1997) 1.19
Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer (1982) 1.16
Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology (1991) 1.15
Transvaginal sonography and serum hCG in monitoring of presumed ectopic pregnancies selected for expectant management. Ultrasound Obstet Gynecol (1995) 1.13
Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res (1992) 1.11
Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem (1989) 1.11
Quantitative detection of low-copy-number mRNAs differing at single nucleotide positions. Biotechniques (2003) 1.10
Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol (1995) 1.10
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer (2004) 1.09
European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer (1999) 1.09
Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology (1988) 1.08
Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res (1991) 1.07
Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer (1986) 1.06
Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer (2011) 1.06
New nomenclature for the human tissue kallikrein gene family. Clin Chem (2000) 1.06
Prostate-specific antigen. Semin Cancer Biol (1999) 1.06
Use of a rapid hCG-beta-subunit radioimmunoassay in acute gynaecological emergencies. Lancet (1980) 1.05
Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol (2001) 1.04
Disappearance of human chorionic gonadotropin and its alpha- and beta-subunits after term pregnancy. Clin Chem (1997) 1.01
Serum levels of human chorionic gonadotropin in nonpregnant women and men are modulated by gonadotropin-releasing hormone and sex steroids. J Clin Endocrinol Metab (1987) 1.01
Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med (1990) 0.99
Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. Int J Cancer (1991) 0.99
Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer (1987) 0.98
Effect of mobilization and immobilization on the healing of contusion injury in muscle. A preliminary report of a histological study in rats. Scand J Rehabil Med (1974) 0.98
Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem (1993) 0.97
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther (2005) 0.97
Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases. Maturitas (2012) 0.97
Suspected ectopic pregnancy: ultrasound findings and hCG levels assessed by an immunofluorometric assay. Br J Obstet Gynaecol (1988) 0.97
Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods (1993) 0.96
HER2 oncogene amplification in extramammary Paget's disease. Histopathology (2003) 0.95
Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. Int J Cancer (2001) 0.95
Serum human chorionic gonadotropin dynamics during spontaneous resolution of ectopic pregnancy. Fertil Steril (1994) 0.95
Activin A/erythroid differentiation factor is induced during human monocyte activation. J Exp Med (1992) 0.94
Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression. Int J Cancer (2001) 0.94
Apparent C trisomy in bone marrow cells. Report of two cases. Scand J Haematol (1970) 0.94
Determination of urinary free cortisol by HPLC. Clin Chem (1997) 0.94
Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer (1999) 0.94
Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer (2009) 0.94
Healing of a crush injury in rat striated muscle. 1. Description and testing of a new method of inducing a standard injury to the calf muscles. Acta Pathol Microbiol Scand A (1975) 0.94
Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome. Matrix Biol (1998) 0.93
Epidemiology of hydatidiform mole in Finland, 1975 to 2001. Eur J Gynaecol Oncol (2005) 0.93
Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas. Int J Cancer (1996) 0.93
Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women. Clin Chem (1992) 0.93
Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab (2000) 0.93
Accurate determination of relative messenger RNA levels by RT-PCR. Nat Biotechnol (1999) 0.93
Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res (1990) 0.92
Tumour-associated trypsin inhibitor (TATI) in ovarian cancer. Br J Cancer (1988) 0.92
Serum CA 125 levels during the menstrual cycle. Br J Obstet Gynaecol (1990) 0.92
Expectant management of ectopic pregnancy. Obstet Gynecol (1992) 0.92
Urinary trypsinogen-2 test strip for acute pancreatitis. Lancet (1996) 0.92
Serum cortisol, dehydroepiandrosterone sulfate, and steroid-binding globulins in preterm neonates: effect of gestational age and dexamethasone therapy. Pediatr Res (1996) 0.91
Essential charged amino acids in the binding of fibronectin to gelatin. Biochem J (1982) 0.91
Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion. Biochem J (1988) 0.91
Human preovulatory follicular fluid, luteinized cells of hyperstimulated preovulatory follicles, and corpus luteum contain placental protein 12. J Clin Endocrinol Metab (1984) 0.91
Developmental changes in 24-hour profiles of luteinizing hormone and follicle-stimulating hormone from prepuberty to midstages of puberty in boys. J Clin Endocrinol Metab (1992) 0.90